GSK Initiates P-III study for RSV Candidate Vaccine Programme for Older Adults

 GSK Initiates P-III study for RSV Candidate Vaccine Programme for Older Adults

GSK Initiates P-III study for RSV Candidate Vaccine Programme for Older Adults

Shots:

  • The first P-III AReSVi 004 study evaluates the immunogenicity, safety, reactogenicity and persistence of RSV candidate vaccine in 1650 adults ≥ aged 60 years. The study is expected to end in early 2024, with interim results expected to be available in the H1’ 2022
  • The second P-III AReSVi 006 study assessing the efficacy of RSV candidate vaccine to help protect older adults against lower-respiratory tract disease and is expected to start in the coming months
  • The P- I/II results of vaccine candidate showed promising safety and immunogenicity in both young and older adults and was well-tolerated. The data presented at the ID Week Congress in October 2020

Click here ­to­ read full press release/ article | Ref: GSK | Image: Caixin Global

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post